Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders for Alnylam Pharmaceuticals, Inc., held on May 18, 2023. The report details the voting outcomes for director elections, executive compensation, and auditor ratification. As of the record date (March 24, 2023), 124,223,536 shares of common stock were issued and outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
Director Elections (Class I)
Stockholders re-elected four Class I directors to serve until the 2026 annual meeting. The voting results were as follows:
- Michael W. Bonney: 101,927,294 For; 11,788,841 Against.
- Yvonne L. Greenstreet, MBChB: 112,375,005 For; 1,347,094 Against.
- Phillip A. Sharp, Ph.D.: 101,384,490 For; 12,335,938 Against.
- Elliott Sigal, M.D., Ph.D.: 110,098,081 For; 3,617,175 Against.
Terms for nine other directors continued following the meeting.
Executive Compensation (Say-on-Pay)
Stockholders approved the compensation of named executive officers in a non-binding advisory vote:
- Votes For: 109,696,830
- Votes Against: 4,017,474
Compensation Vote Frequency
Stockholders recommended an annual frequency for future advisory votes on executive compensation:
- One Year: 113,457,307 votes
- Two Years: 17,317 votes
- Three Years: 250,908 votes
Auditor Ratification
Stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2023:
- Votes For: 116,139,990
- Votes Against: 1,842,688
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The Company intends to hold annual advisory votes on executive compensation until the next required frequency vote.
Investor Verification Checklist
- Verify the specific terms of office for the newly elected Class I directors (Michael W. Bonney, Yvonne L. Greenstreet, Phillip A. Sharp, Elliott Sigal).
- Confirm the Company's commitment to annual Say-on-Pay votes based on the stockholder recommendation.
- Review the full proxy statement for detailed biographical information on directors and executive compensation specifics not included in this summary.
- Check subsequent filings (10-K or 10-Q) for the financial metrics absent from this 8-K.